Literature DB >> 24725480

Theranostic applications of antibodies in oncology.

Emmy D G Fleuren1, Yvonne M H Versleijen-Jonkers2, Sandra Heskamp3, Carla M L van Herpen2, Wim J G Oyen3, Winette T A van der Graaf2, Otto C Boerman3.   

Abstract

Targeted therapies, including antibodies, are becoming increasingly important in cancer therapy. Important limitations, however, are that not every patient benefits from a specific antibody therapy and that responses could be short-lived due to acquired resistance. In addition, targeted therapies are quite expensive and are not completely devoid of side-effects. This urges the need for accurate patient selection and response monitoring. An important step towards personalizing antibody treatment could be the implementation of theranostics. Antibody theranostics combine the diagnostic and therapeutic potential of an antibody, thereby selecting those patients who are most likely to benefit from antibody treatment. This review focuses on the clinical application of theranostic antibodies in oncology. It provides detailed information concerning the suitability of antibodies for theranostics, the different types of theranostic tests available and summarizes the efficacy of theranostic antibodies used in current clinical practice. Advanced theranostic applications, including radiolabeled antibodies for non-invasive functional imagining, are also addressed. Finally, we discuss the importance of theranostics in the emerging field of personalized medicine and critically evaluate recent data to determine the best way to apply antibody theranostics in the future.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; Biomarker; Molecular imaging; Personalized medicine; Theranostics

Mesh:

Substances:

Year:  2014        PMID: 24725480      PMCID: PMC5528531          DOI: 10.1016/j.molonc.2014.03.010

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  80 in total

1.  Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.

Authors:  Abhay S Gokhale; Jyoti Mayadev; Brad Pohlman; Roger M Macklis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Authors:  Shankar Vallabhajosula; Stanley J Goldsmith; Lale Kostakoglu; Mathew I Milowsky; David M Nanus; Neil H Bander
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

Review 3.  HER2 therapies and gastric cancer: a step forward.

Authors:  Ramon Andrade de Mello; Andrea Marin Marques; António Araújo
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

4.  Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

Authors:  Katia Scotlandi; Maria Cristina Manara; Massimo Serra; Maria Teresa Marino; Selena Ventura; Cecilia Garofalo; Marco Alberghini; Giovanna Magagnoli; Stefano Ferrari; Jose Antonio Lopez-Guerrero; Antonio Llombard-Bosch; Piero Picci
Journal:  Eur J Cancer       Date:  2011-02-21       Impact factor: 9.162

5.  Principles, problems, and strategies in the use of antigenic mixtures for the enzyme-linked immunosorbent assay.

Authors:  G E Kenny; C L Dunsmoor
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

6.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Authors:  Barbara Burtness; Meredith A Goldwasser; William Flood; Bassam Mattar; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

Review 7.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Expression and clinical relevance of MET and ALK in Ewing sarcomas.

Authors:  Emmy D G Fleuren; Melissa H S Roeffen; William P Leenders; Uta E Flucke; Myrella Vlenterie; Hendrik W Schreuder; Otto C Boerman; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

9.  Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.

Authors:  C R Divgi; S Welt; M Kris; F X Real; S D Yeh; R Gralla; B Merchant; S Schweighart; M Unger; S M Larson
Journal:  J Natl Cancer Inst       Date:  1991-01-16       Impact factor: 13.506

10.  Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression.

Authors:  Marian G W Scheer; Thamar H Stollman; Otto C Boerman; Kiek Verrijp; Fred C G J Sweep; William P J Leenders; Theo J M Ruers; Wim J G Oyen
Journal:  Eur J Cancer       Date:  2008-07-14       Impact factor: 9.162

View more
  23 in total

Review 1.  In vivo imaging with antibodies and engineered fragments.

Authors:  Amanda C Freise; Anna M Wu
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

2.  Deciding site of biopsy at metastatic relapse.

Authors:  Ajit Venniyoor
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 3.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

Review 4.  [Simultaneous whole-body PET-MRI in pediatric oncology : More than just reducing radiation?].

Authors:  S Gatidis; B Gückel; C la Fougère; J Schmitt; J F Schäfer
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 5.  Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents.

Authors:  Francesca Garello; Yulia Svenskaya; Bogdan Parakhonskiy; Miriam Filippi
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

6.  Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma.

Authors:  Sarah McCollum; Austen Kalivas; Matthew Kirkham; Kaden Kunz; Jeffrey Okojie; Adriene Pavek; Jared Barrott
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

7.  CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes.

Authors:  Jiangnan Liu; Bin Yi; Zhe Zhang; Yi Cao
Journal:  Front Med       Date:  2016-04-18       Impact factor: 4.592

Review 8.  Theranostic applications of antibodies in oncology.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

9.  On chip analysis of CNS lymphoma in cerebrospinal fluid.

Authors:  Anna Turetsky; Kyungheon Lee; Jun Song; Randy J Giedt; Eunha Kim; Alexandra E Kovach; Ephraim P Hochberg; Cesar M Castro; Hakho Lee; Ralph Weissleder
Journal:  Theranostics       Date:  2015-04-17       Impact factor: 11.556

Review 10.  IGF-IR Targeted Therapy: Past, Present and Future.

Authors:  Joseph A M J L Janssen; Aimee J Varewijck
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.